Objective In patients with acute myocardial infarction (AMI), angiographic slow/no-flow during percutaneous coronary intervention (PCI) may lead to unfavorable outcomes. The aim of our study was to investigate the predictors and long-term prognosis of AMI patients with angiographic slow/no-flow.
Introduction
slow/no-flow in patients who have had an acute coronary event (8, 9) . In addition, other studies have shown that blood serum markers of inflammation, such as C-reactive protein, peripheral white blood cell count, or plasma glucose level, may predict the increased risk of instability caused by atherosclerotic plaque. An elevation in these serum markers after the onset of an AMI has been reported to be associated with a significantly worse prognosis (3, (10) (11) (12) (13) .
Methods to predict effectively the development of angiographic slow/no-flow have not yet been established. The purpose of this study was to investigate clinical and angiographic features that could effectively predict angiographic slow/no-flow prior to revascularization and also to predict the long-term prognosis for patients.
Methods

Study population
Between January 2000 and December 2003, 240 consecutive AMI patients, who were admitted within 24 hours after the onset of symptoms, underwent an emergency PCI at Matsue Red Cross Hospital, Matsue, Japan. An AMI was defined by the following characteristics: chest pain consistent with any ongoing myocardial ischemia persisting longer than 30 minutes, ischemic electrocardiographic changes, and a greater than threefold increase in serum creatine kinase levels. Four patients were excluded from the analysis because of cardiogenic shock on admission. A further 8 patients with either significant left main disease or severe multivessel disease who required urgent surgical intervention were also excluded. Therefore, this study was based on the remaining 228 patients. The institutional review board approved the study and written informed consent was obtained from all patients.
Study protocol
All patients received intravenous heparin to achieve an activated clotting time of >250 seconds. We performed coronary angiography using the right brachial approach to determine the culprit lesion and collateral channels. We gave an intracoronary bolus dose of 0.2 mg nitroglycerine to all patients immediately after reestablishing the antegrade flow. The collateral channels were graded according to a previously described method (14) . PCI was performed as a reperfusion therapy in all AMI patients: coronary stents were used in 218 patients and conventional balloon angioplasty in 10 patients. During the study period, only bare-metal stents were used. The infarct-related artery was the only target of the procedure. We performed optimal coronary intervention after evaluation of the lesion morphology. The decisionmaking for the PCI strategy was left to the discretion of the individual PCI cardiologist. Angiographic slow/no-flow during PCI was defined as Thrombolysis in Myocardial Infarction (TIMI) flow grade !2 during the procedure without evidence of dissection, stenosis, or vasospasm. The TIMI flow grades were determined by the consensus of three investigators. Angiographic criteria of a <50% residual stenosis and TIMI-3 were used to determine the end of the interventional procedure.
Quantitative coronary angiography was performed before and immediately after the procedure using the edge detection algorithm (15) and by selecting end-diastolic frames demonstrating the stenosis in its most severe and nonforeshortened projection. The minimal luminal diameter, reference vessel diameter, and lesion length were calculated with a contrast-filled guiding catheter used as the calibration standard. If a culprit lesion was occluded (TIMI-0), the lesion length was calculated after opening the lesion either by wiring or by dilatation using a small balloon before optimal coronary intervention. We defined large vessels of the infarct-related artery as having a reference vessel diameter of "4.0 mm using the definition from the previous report (16), and a long lesion of the infarct-related artery as a lesion length "10 mm using the criteria of type B lesions from the guidelines of the lesion morphology (17). We used the simple subset classification of Forrester and colleagues to assess hemodynamic status (18). The patients were treated with ticlopidine (200 mg/day) for 4 weeks after the procedure if a stent deployment was performed. Aspirin (81 to 162 mg/day) was administered indefinitely to each patient. Platelet glycoprotein IIb/IIIa inhibitors were not administered to any patient because they were not available in our country.
Blood samples for measuring white blood cell count, Creactive protein, and glucose were taken from a peripheral vessel in the Emergency Room before the administration of any medication. Acute hyperglycemia was defined as a blood glucose level "180 mg/dl on admission to the hospital as stated by the previous studies (13). Samples for measuring serum creatine kinase levels were taken on admission and subsequently for every 3 hours during the first 24 hours.
Clinical follow-up
Patients in this study were followed up at 6-and 12month intervals after the AMI event. Clinical information regarding major adverse cardiac and cerebrovascular events (MACCE), including any cardiac death, development of heart failure requiring hospitalization, or ischemic stroke, was obtained from telephonic interviews with patients, contact with patients' physicians, and hospital records. Heart failure was defined as a hospital readmission for which heart failure was the primary reason. Ischemic stroke was defined as a new focal neurological deficit of sudden onset lasting "24 hours that was not caused by hemorrhage with corroborative imaging evidence by computed tomography or magnetic resonance imaging. All patients who did not experience adverse events were followed up for an entire 12month period.
T a b l e 1 . B a s e l i n e Cl i n i c a l Ch a r a c t e r i s t i c s
Statistical analysis
Standard statistical methods were used. The results are presented as mean±SD or frequency. The comparison of the data between the two groups was performed by an unpaired t-test for continuous variables and by a chi-square test or Fisher's exact test for discrete variables. Multivariate logistic regression models were used to determine the predictors of angiographic slow/no-flow. The independent variables included in this model were the clinical and angiographic features prior to revascularization. If the independent predictors were any serum markers and/or angiographic measurements as a result of multivariate analysis, optimal threshold values (highest combination of sensitivity/specificity) were identified via the receiver operating characteristic (ROC) curve analysis. We evaluated the effects on event-free survival rate by predicting angiographic slow/no-flow. Event-free survival was analyzed with Kaplan-Meier method and log-rank used for comparisons between curves. If the Kaplan-Meier method revealed a significant relation between the events and angiographic slow/no-flow, Cox multivariate analysis was used to determine whether the relation was independent of other important clinical predictors, such as age, gender, hypertension, diabetes mellitus, blood glucose on admission, anterior wall infarction, multivessel coronary disease, Forrester subset !2, time to reperfusion, and angiographic slow/no-flow, which were added to the variable in a Cox model. All p<0.05 were considered statistically significant. Analyses were done using the statistical software Dr. SPSS II 11.0J (SPSS Japan Inc., Tokyo, Japan).
Results
Patient characteristics
Among the 228 patients who underwent PCI, angiographic slow/no-flow during PCI occurred in 36 patients (16%) and did not occur in 192 (84%). The baseline clinical characteristics are shown in Table 1 . The plasma glucose level on admission was higher in the patients with angio-T a b l e 2 . An g i o g r a p h i c a n d P r o c e d u r a l Ch a r a c t e r i s t i c s o f S t u d y P a t i e n t s graphic slow/no-flow than in those without (201.6±64.9 mg/ dl vs. 174.9±68.0 mg/dl, p=0.03); however, there were no significant differences between the two groups with regard to white blood cell count, C-reactive protein values on admission, or peak serum creatine kinase levels.
Angiographic and procedural characteristics
The angiographic and procedural characteristics of the 2 groups are summarized in Table 2 . Quantitative coronary angiography analysis demonstrated that the patients in the slow/no-flow group had a longer lesion length (14.8±8.72 mm vs. 9.76±6.78 mm, p<0.001) and larger initial reference vessel diameter (3.14±0.63 mm vs. 2.90±0.57 mm, p=0.025) than did those in the normal flow group. The use of an intra-aortic balloon pump, to augment coronary blood flow and improve hemodynamic stability, was significantly higher in the patients with angiographic slow/no-flow during the PCI than in those without PCI (36.1% vs. 9.9%, p<0.001).
Predictors of angiographic slow/no-flow during PCI
The independent predictors of angiographic slow/no-flow during the PCI are shown in Table 3 . The use of an intraaortic balloon pump was excluded from this multivariate lo-gistic regression model, because it was inserted in most patients to augment coronary blood flow after the occurrence of the angiographic slow/no-flow. Multivariate logistic regression analysis revealed that a long lesion length (!10 mm)(odds ratio [OR], 3.514; 95% confidence interval [CI], 1.505-8.206; p=0.004) and hyperglycemia on admission (! 180 mg/dl)(OR, 3.011; 95 % CI, 1.211-7.485; p=0.018) were significant and independent predictors of angiographic slow/no-flow.
Long-term outcomes and predictors of cardiac events
The median follow-up time was 354±78 days. The 12month follow-up was completed in 226 (99%) of the patients, and during this time, MACCE occurred in 16 patients; 10 patients died of cardiogenic events (cardiac rupture, severe heart failure, or sudden cardiac death), 2 developed heart failure requiring hospitalization, and 4 had ischemic strokes. According to the Kaplan-Meier method, the incidence of MACCE and cardiac death during the 12month follow-up period were significantly higher in the slow/no-flow group compared with the normal flow group (Figs. 1, 2) . Table 4 lists the results of the multivariate Cox 
. Co x P r o p o r t i o n a l Ha z a r d s An a l y s e s o f I n d e p e n d e n t P r e d i c t o r s f o r MACCE a n d Ca r d i a c Mo r t a l i t y
analysis. The only parameters associated with cardiac mortality were age and angiographic slow/no-flow, and the only parameters associated with the prediction of any MACCE were age, multivessel coronary disease, angiographic slow/ no-flow, and Forrester subset !2.
F i g u r e 1 . Ka p l a n -Me i e r e s t i ma t e s o f MACCE f o r AMI p at i e n t s wi t h a n g i o g r a p h i c s l o w/ n o -f l o w o r wi t h n o r ma l f l o w. MACCE , ma j o r a d v e r s e c a r d i a c a n d c e r e b r o v a s c u l a r e v e n t s .
F i g u r e 2 . Ka p l a n -Me i e r e s t i ma t e s o f c a r d i a c s u r v i v a l f o r AMI p a t i e n t s wi t h a n g i o g r a p h i c s l o w/ n o -f l o w o r t h o s e wi t h n o r ma l f l o w.
F i g u r e 3 . T h e r e c e i v e r o p e r a t i n g c h a r a c t e r i s t i c c u r v e s f o r t h e l e s i o n l e n g t h i n t h e i n f a r c t -r e l a t e d a r t e r y a n d b l o o d g l uc o s e l e v e l o n a d mi s s i o n i n p r e d i c t i n g a n a n g i o g r a p h i c s l o w/ n o -f l o w i n p a t i e n t s wi t h AMI . T h e o p t i ma l c u t -o f f v a lu e s o f t h e s e 2 p a r a me t e r s a r e r e p r e s e n t e d o n t h e c u r v e s . AUC: a r e a u n d e r t h e c u r v e
Determination of the optimal cut-off values for predicting angiographic slow/no-flow
The optimal cut-off points of the lesion length and blood glucose level on admission were defined retrospectively on the basis of the ROC curves. Using the lesion length to predict the angiographic slow/no-flow, a cut-off of !10.45 mm had a sensitivity of 64%, specificity of 70%, positive predictive value (PPV) of 29%, negative predictive value (NPV) of 91%, and area under the curve (AUC) of 0.717 (95% CI, 0.625-0.809; p<0.001). For blood glucose on admission, a cut-off of !187.5 mg/dl had a sensitivity of 56%, specificity of 70%, PPV of 26%, NPV of 89%, and AUC of 0.656 (95% CI, 0.567-0.746; p=0.003) (Fig. 3) ; however, there was a sensitivity of 89%, specificity of 51%, PPV of 25%, and NPV of 96% by combining those 2 parameters.
Discussion
The results of the present study suggest that angiographic slow/no-flow is a marker of cardiac risk in AMI patients. (3, (10) (11) (12) (13) . In this study, we found no relationship between white blood cell count, C-reactive protein level, or angiographic slow/no-flow, although our results indicated that angiographic slow/no-flow occurred more frequently in patients with acute hyperglycemia on ad- (8, 9) ; however, performing an intravascular ultrasound in all AMI patients would probably be impracticable, and hence we simply investigated the relationship between angiographic findings before optimal coronary intervention and angiographic slow/no-flow. According to the angiographic findings in this study, we found that a long lesion was an independent predictor of angiographic slow/no-flow. The angiographic morphological features before optimal coronary intervention may be simple and efficacious clinical parameters for predicting angiographic slow/no-flow.
In the results of multivariate analysis, the independent predictors of angiographic slow/no-flow were long lesion in the infarct-related artery and acute hyperglycemia irrespective of a history of diabetes mellitus. Additionally, we found that there was a high sensitivity (89%) by combining the optimal cut-off values of lesion length (10.45 mm) with blood glucose level on admission (187.5 mg/dl) for predicting angiographic slow/no-flow as identified by analysis of the ROC curves. Several previous reports have suggested that elevated white blood cell counts and C-reactive protein levels are associated with vulnerability to culprit coronary lesions in AMI patients, and hyperglycemia is associated with an impairment of microvascular function and can cause angiographic slow/no-flow
mission. Several mechanisms could explain the association between hyperglycemia and angiographic slow/no-flow. Acute hyperglycemia increases intercellular adhesion molecule-1 (ICAM-1) or P-selectin level (19, 20), which would augment the plugging of the capillaries with leukocytes and contribute to the no-flow phenomenon (21). It has been reported that hyperglycemia aggravates plateletdependent thrombus formation (22), attenuates endotheliumdependent vasodilatation (23), and reduces collateral blood flow by adversely affecting nitric oxide availability (24). These changes are associated with impairment in microvascular function before reperfusion and are related to angiographic slow/no-flow. A recent study suggested that stress hyperglycemia related to myocardial infarction was associated with an increased risk of in-hospital mortality in patients with and without diabetes (13). The present study also indicated that AMI patients in the slow/no-flow group had significantly higher plasma glucose levels on admission and a significantly higher mortality, irrespective of a history of diabetes mellitus; however, stress hyperglycemia is an imperfect marker of cardiac damage, as many factors in addition to stress hormones contribute to the regulation of the glucose concentration. It remains controversial whether acute hyperglycemia predisposes patients to an adverse outcome or is simply a consequence of the large infarct size. Previous reports have described intravascular ultrasound lesion morphologies in relation to the angiographic no-flow phenomenon in acute coronary syndrome patients
In the catheterization laboratory, the clinical presentation of angiographic slow/no-flow during the short-term intervention in myocardial infarction patients is often sudden and dynamic. Angiographic slow/no-flow has also been linked to ventricular arrhythmias (25), early congestive heart failure, left ventricular remodeling (7), and even cardiac rupture (26) . We also showed that event-free survival in the slow/ no-flow group was lower than that in the normal flow group during the follow-up period. Recently, several anti-embolic devices have become available for use to prevent distal em-bolism of thrombus or plaque debris caused by the PCI. Small studies using distal protection devices and thrombectomy devices have shown encouraging results in improving the distal perfusion (27, 28) , but large randomized AMI trials failed to demonstrate any positive effect of routine embolic protection on myocardial reperfusion or clinical outcome (29, 30) . In this study, we showed that combining the optimal cut-off values of lesion length and blood glucose level on admission to predict angiographic slow/no-flow had a high sensitivity and NPV. Therefore, it may be possible to select AMI patients at high risk of angiographic slow/noflow using the combination of these parameters, and conversely, to predict a lower risk of angiographic slow/no-flow if both these parameters were also low. We suggest that distal protection devices should not be used routinely but only for AMI patients at high risk for angiographic slow/no-flow. Further investigation in larger, randomized trials will be necessary to clarify any potential beneficial effect of distal protection devices in these high-risk patients.
There were several limitations to our study. This was a single-center, non-randomized, and retrospective study with a relatively small number of patients. Glycoprotein IIb/IIIa inhibitors were not used for any of the patients in this study, because they are not approved for clinical use in Japan. Although all patients underwent a PCI within 30 minutes after taking blood samples upon hospital admission, we were unable to measure changes in blood glucose level before the PCI. We did not perform a glucose tolerance test in patients without any history of diabetes mellitus or a high HbA1c value, nor did we analyze serum insulin, catecholamine, or free fatty acid levels, which may have provided important additional information. Finally, myocardial contrast echocardiography, ST-segment resolution, and angiographic "blushing" scores may provide a more meaningful assessment of reperfusion efficacy than the TIMI flow grade; however, we analyzed this using the TIMI flow grade, which at the time was still the most common assessment for reperfusion.
In conclusion, lesion length and blood glucose level on admission can be used to stratify AMI patients into a lower or higher risk for angiographic slow/no-flow before optimal coronary intervention. In addition, angiographic slow/noflow predicts an adverse outcome in AMI patients. associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 150: 814-820, 2005. 4 Morishima 
